ALLMedicine™ Acute Megakaryoblastic Leukemia Center
Research & Reviews 82 results
https://doi.org/10.1007/s12185-020-03066-7 10.1182/blood-2008-11-163501 10.1182/blood-2007-01-069542 10.1182/blood-2005-06-2448 10.1182/blood-2007-10-118810 10.1111/j.1365-2141.2008.07231.x 10.1182/blood.V80.6.1521.1521 10.1016/0046-8177(91)90111-2 10.1007/s12185-013-1487-5 10.1111/bjh.15390 10.1182/blood-2003-02-0390 10.1182/blood-2010-05-282426 10.1038/bmt.2012.244 10.1182/blood-2013-07-515148 10.1002/ajmg.a.61748
International Journal of Hematology; Yamato G, Park MJ et. al.
Jan 4th, 2021 - Transient abnormal myelopoiesis (TAM) is a unique clonal myeloproliferation characterized by immature megakaryoblasts that occurs in 5-10% of neonates with Down syndrome (DS). Although TAM regresses spontaneously in most patients, approximately 20...
Clinical Lymphoma, Myeloma & Leukemia; Wang Y, Lu A et. al.
Dec 1st, 2020 - Acute megakaryoblastic leukemia (AMKL) is a biologically heterogeneous subtype of acute myeloid leukemia that originates from megakaryocytes. Patients with AMKL with non-Down syndrome (DS) had a poorer prognosis. However, clear prognostic indicato...
Cancer Gene Therapy; Vukadin L, Kim JH et. al.
Nov 28th, 2020 - A high incidence of acute megakaryoblastic leukemia (AMKL) in Down syndrome patients implies that chromosome 21 genes have a pivotal role in AMKL development, but the functional contribution of individual genes remains elusive. Here, we report tha...
Journal of Pediatric Hematology/oncology; Feng J, Leung AWK et. al.
Oct 30th, 2020 - There is no established effective treatment for patients with t(1;22)(p13;q13) acute megakaryoblastic leukemia (AMKL) and hepatic fibrosis. Here we report the outcomes of 2 t(1;22)(p13;q13) AMKL patients with hepatic fibrosis. One patient died fro...
Cytometry. Part B, Clinical Cytometry; Panda D, Chatterjee G et. al.
Aug 31st, 2020 - In 2016, Children Oncology Group (COG) described a new high-risk subtype of acute myeloid leukemia (AML) with a distinct immunophenotypic-signature, RAM-phenotype (RAM-AML). Data on clinical and laboratory features of RAM-AML are still limited to ...
Clinicaltrials.gov 2 results
Feb 18th, 2018 - PRIMARY OBJECTIVES: I. Determine the safety profile of alisertib in patients with acute megakaryoblastic leukemia (AMKL) and in patients with myelofibrosis (MF). SECONDARY OBJECTIVES: I. Determine preliminary efficacy of alisertib in both populati...
May 17th, 2016 - Study Subtype: Ancillary/Correlative Observational Study Model: Cohort Time Perspective: Retrospective Biospecimen Retention: Samples With DNA Biospecimen Description: Cryopreserved mRNA Study Population Description: Samples from AAML0531 Sampling...
News 1 results
Jan 24th, 2017 - Micrograph showing AMKL Image courtesy of St. Jude Children’s Research Hospital and Tina Motroni Research has revealed genetic alterations that may prove useful for predicting treatment outcomes in pediatric patients with acute megakaryoblastic le.